Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis
S Deitelzweig, E Bergrath, M di Fusco, A Kang… - Future …, 2022 - Taylor & Francis
Aim: To compare real-world effectiveness/safety of non-vitamin K antagonist oral
anticoagulants and vitamin K antagonists among patients with non-valvular atrial fibrillation …
anticoagulants and vitamin K antagonists among patients with non-valvular atrial fibrillation …
Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review …
D Caldeira, FB Rodrigues, M Barra, AT Santos… - Heart, 2015 - heart.bmj.com
Objective Non-vitamin K antagonist oral anticoagulants (NOACs) are efficacious and safe
antithrombotic drugs but the non-availability of an antidote for potential fatal haemorrhagic …
antithrombotic drugs but the non-availability of an antidote for potential fatal haemorrhagic …
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
H Heidbuchel, P Verhamme, M Alings, M Antz… - Europace, 2013 - academic.oup.com
New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to
prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and …
prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and …
Inappropriate dose of nonvitamin-K antagonist oral anticoagulants: prevalence and impact on clinical outcome in patients with nonvalvular atrial fibrillation
Background Limited real-world data are available regarding the outcome of patients treated
with inappropriate dose of nonvitamin-K antagonist oral anticoagulants (NOACs). Objective …
with inappropriate dose of nonvitamin-K antagonist oral anticoagulants (NOACs). Objective …
Non-vitamin K antagonist oral anticoagulants and antiplatelet therapy for stroke prevention in patients with atrial fibrillation: a meta-analysis of randomized controlled …
S Kumar, SB Danik, RK Altman, CD Barrett… - Cardiology in …, 2016 - journals.lww.com
Non-vitamin K antagonist oral anticoagulants (NOACs) are frequently used to prevent stroke
in patients with atrial fibrillation. These patients are often also on aspirin or other antiplatelet …
in patients with atrial fibrillation. These patients are often also on aspirin or other antiplatelet …
Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral …
MV Huisman, GLORIA-AF Investigators, CS Ma… - EP …, 2016 - academic.oup.com
Aims The introduction of non-VKA oral anticoagulants (NOACs), which differ from the earlier
vitamin K antagonist (VKA) treatments, has changed the approach to stroke prevention in …
vitamin K antagonist (VKA) treatments, has changed the approach to stroke prevention in …
Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
L Friberg, J Oldgren - Open Heart, 2017 - openheart.bmj.com
Aims Non-vitamin K antagonist oral anticoagulants (NOACs) were in pivotal randomised
controlled trials at least non-inferior to warfarin for stroke prevention in atrial fibrillation, but …
controlled trials at least non-inferior to warfarin for stroke prevention in atrial fibrillation, but …
EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary
H Heidbuchel, P Verhamme, M Alings… - European heart …, 2013 - academic.oup.com
New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to
prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and …
prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and …
Non‐vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights
CR Kumana, BMY Cheung, DCW Siu… - Cardiovascular …, 2016 - Wiley Online Library
Summary Background and Objectives Benefits and/or harms (including costs) of non‐
vitamin K oral anticoagulants (NOAC s) versus warfarin therapy need appreciation in relative …
vitamin K oral anticoagulants (NOAC s) versus warfarin therapy need appreciation in relative …
[HTML][HTML] Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation
JC Lega, L Bertoletti, C Gremillet, C Chapelle… - PloS one, 2014 - journals.plos.org
Aims The well-known limitations of vitamin K antagonists (VKA) led to development of new
oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta …
oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta …